Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, cardiovascular, and immunology therapeutics. Its portfolio is concentrated on three top-selling drugs — Revlimid, Eliquis, and Opdivo — comprising 57% of 2025 revenue. The company is navigating a patent cliff transition.

• Oncology Franchise: Opdivo (~$2.5B/quarter, though down ~4% Y/Y as the U.S. market converts to the subcutaneous Opdivo Qvantig formulation, which is itself annualizing above $1B).
• Cardiovascular Leadership: Eliquis (~$4.5B in Q2 2026, +21% Y/Y) remains a top global anticoagulant with continued share gains; FY2026 Eliquis growth guided to 20-25%.
• Growth Portfolio Diversification: Newer drugs (Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy) delivered $7.6B in Q2 2026 (+15% Y/Y), now outweighing the legacy, patent-exposed portfolio ($5.4B, declining) — evidence the post-patent-cliff transition is gaining traction.
• First-in-Class Pipeline Optionality: Cobenfy (first non-dopaminergic antipsychotic), CELMoD candidates iberdomide (FDA Breakthrough Therapy/Priority Review, PDUFA 08/17/2026) and mezigdomide (positive interim Phase III SUCCESSOR-2 readout), positioned as next-generation Revlimid/Pomalyst successors in multiple myeloma.
• BioNTech Oncology Alliance: Global co-development/co-commercialization deal for bispecific pumitamig (BNT327) across multiple solid tumors, sharing costs and profits equally and broadening the next-generation oncology pipeline beyond BMS's own R&D.

• 2026-08-10: BMS announced a ~$2.3B investment in a new 600,000 sq. ft. multi-modal manufacturing campus in Houston, TX (Generation Park), creating ~500 skilled jobs plus ~2,000 construction jobs (2027-2030), part of the company's broader $40B, five-year U.S. manufacturing/R&D commitment.
• 2026-07-30 (Q2 2026 earnings): Revenue rose to ~$13.0B (+6% Y/Y); non-GAAP EPS $2.04 beat consensus of ~$1.59-1.60; company raised full-year 2026 revenue guidance to $49-50B and non-GAAP EPS guidance to $6.75-7.00.
• 2026-07-29: Shares set a new 52-week high (~$68.10) following the earnings beat, up ~15.5% over the trailing month and ~21% YTD.
• 2026-05 (ASCO 2026): BMS presented 60+ data disclosures across its oncology pipeline, including a positive interim PFS readout for mezigdomide in the Phase III SUCCESSOR-2 trial and combination data for iberdomide in newly diagnosed multiple myeloma — both positioned to succeed Revlimid/Pomalyst as generic erosion continues.
• 2026 (Cobenfy launch trajectory): Continued U.S. commercial ramp of Cobenfy in schizophrenia, with a UK launch planned in 2026 at U.S.-equivalent list pricing; analysts (e.g., Cantor Fitzgerald) project the drug approaching ~$1B in annual sales in 2026, scaling toward $3B+ by 2030.
• Ongoing (patent cliff): Full generic competition for Revlimid (lenalidomide) expanded through the volume-limited settlement structure, with Pomalyst generics also expected to enter the U.S. market in Q1 2026 — Legacy Portfolio revenue continues to decline (-5% Y/Y in Q2 2026) even as Eliquis and the Growth Portfolio more than offset the erosion at the total-company level.

• ⚠️ Patent Cliff / Legacy Erosion: Revlimid and Pomalyst face expanding generic competition through 2026, with Legacy Portfolio revenue already declining; the pace of erosion versus Growth Portfolio offset remains a key swing factor for out-year revenue.
• ⚠️ Opdivo Franchise Transition: Core IV Opdivo revenue is shrinking (-4% Y/Y in Q2 2026) as the market converts to Opdivo Qvantig; successful conversion economics (pricing, market access) are not yet fully proven at scale, and BMS trails Merck's Keytruda by a wide margin in immuno-oncology share.
• ⚠️ Pipeline Execution Risk: The bull case leans heavily on CELMoDs (iberdomide, mezigdomide), Cobenfy, and the BioNTech-partnered pumitamig reaching commercial scale; delayed approvals (e.g., iberdomide's 08/17/2026 PDUFA date), disappointing pivotal data, or slower-than-expected uptake would pressure the growth narrative.
• ⚠️ Capital Deployment / M&A Risk: Continued large licensing/M&A commitments (BioNTech's up-to-$11.1B deal, the $40B U.S. manufacturing pledge including the new $2.3B Houston campus) add integration and capital-allocation risk against a backdrop of already-elevated legacy revenue declines.
• ⚠️ Competitive Intensity: Oncology and immunology overlap heavily with Merck, J&J, Roche, AbbVie, and Pfizer, all of which are also investing aggressively in next-generation immuno-oncology and bispecific/ADC pipelines.